

Philip Haywood

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/15296/publications.pdf>

Version: 2024-02-01

25
papers

539
citations

933447

10
h-index

642732

23
g-index

25
all docs

25
docs citations

25
times ranked

858
citing authors

#	ARTICLE	IF	CITATIONS
1	Paying for value: options for value-based payment reform in Australia. Australian Health Review, 2022, 46, 129-133.	1.1	7
2	Evaluation of the Victorian Healthy Homes Program: protocol for a randomised controlled trial. BMJ Open, 2022, 12, e053828.	1.9	0
3	Clinical assessment of chemotherapy-induced peripheral neuropathy: a discrete choice experiment of patient preferences. Supportive Care in Cancer, 2021, 29, 6379-6387.	2.2	4
4	Differences in health care spending and utilization among older frail adults in high-income countries: ICCONIC hip fracture persona. Health Services Research, 2021, 56, 1335-1346.	2.0	22
5	International comparison of health spending and utilization among people with complex multimorbidity. Health Services Research, 2021, 56, 1317-1334.	2.0	24
6	Differences in health outcomes for high-need, high-cost patients across high-income countries. Health Services Research, 2021, 56 Suppl 3, 1347-1357.	2.0	13
7	A methodology for identifying high-need, high-cost patient personas for international comparisons. Health Services Research, 2021, 56, 1302-1316.	2.0	5
8	Health system costs and days in hospital for colorectal cancer patients in New South Wales, Australia. PLoS ONE, 2021, 16, e0260088.	2.5	5
9	Heat-related mortality: an urgent need to recognise and record. Lancet Planetary Health, The, 2020, 4, e171.	11.4	13
10	Cost of Salmonella Infections in Australia, 2015. Journal of Food Protection, 2019, 82, 1607-1614.	1.7	13
11	Real-World Cost Effectiveness of Mandatory Folic Acid Fortification of Bread-Making Flour in Australia. Applied Health Economics and Health Policy, 2019, 17, 243-254.	2.1	5
12	Cost-Effectiveness of Reclassifying Triptans in Australia: Application of an Economic Evaluation Approach to Regulatory Decisions. Value in Health, 2019, 22, 293-302.	0.3	4
13	The prevalence of persistence and related health status: An analysis of persistently high healthcare costs in the short term and medium term. Social Science and Medicine, 2018, 211, 147-156.	3.8	4
14	Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort. BMJ Open, 2017, 7, e014439.	1.9	15
15	Long-term health care costs for patients with prostate cancer: a population-wide longitudinal study in New South Wales, Australia. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 160-171.	1.1	10
16	Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study. PLoS ONE, 2017, 12, e0184360.	2.5	325
17	Cost of cancer care for patients undergoing chemotherapy: The elements of cancer care study. Asia-Pacific Journal of Clinical Oncology, 2015, 11, 178-186.	1.1	13
18	Can administrative data be used to measure chemotherapy side effects?. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 215-222.	1.4	3

#	ARTICLE	IF	CITATIONS
19	Delays in access to affordable medicines: putting policy into perspective – authors’ response. Australian Health Review, 2014, 38, 16.	1.1	0
20	Delays in access to affordable medicines: putting policy into perspective. Australian Health Review, 2012, 36, 412.	1.1	29
21	Chemotherapy Administration. Pharmacoeconomics, 2012, 30, 1173-1186.	3.3	3
22	Nursing Takes Time: Workload Associated With Administering Cancer Protocols. Clinical Journal of Oncology Nursing, 2010, 14, 735-741.	0.6	16
23	Alternatives to for-profit corporatisation: The view from general practice. Australian Journal of Primary Health, 2005, 11, 78.	0.9	1
24	Theory verses empiricism in health economics. European Journal of Health Economics, 2003, 4, 90-95.	2.8	3
25	Diagnosis and prognosis of Australia’s health information for evidence-based policy. Journal of Health Services Research and Policy, 2002, 7, 40-45.	1.7	2